Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 68Recurrence 17Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Renal Insufficiency 2Plasmacytoma 2Myeloproliferative Disorders 2Chromosome 17 deletion 2Amyloidosis 2Thrombocytosis 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pomalidomide 1Lenalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Malignant Plasma Cell Neoplasms × pomalidomide × Clear all
NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
162 enrolled
Plasma cell

Malignant Plasma Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡